Detailed price information for Calcimedica Inc (CALC-Q) from The Globe and Mail including charting and trades.

FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...

ProKidney Corp. targets diabetic CKD with Rilparencel and expects Q2 2027 eGFR slope data for accelerated approval. Find out ...

CFO Daniel Perotti stated, "PFSI reported net income of $107 million in the fourth quarter or $1.97 in earnings per share for an annualized ROE of 10%. These results included $1 million of fair value ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

The nonprofit expects to spend another $6 million over the next couple years constructing its new campus. It’ll have a full gym, basketball court and space that complementary nonprofits can use for ...

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that ...

For a rugby legend like Rocky Elsom, the roar of the crowd has been replaced by the deafening silence of legal limbo.

Aurora Labs used the December 2025 quarter to move from development toward early commercial execution, particularly in ...

The nomination of Kevin Warsh as Federal Reserve Chairman could amount to a historic reform of the nation's central bank.

Bell Potter thinks this biotech could be cheap and heading much higher. The post Could Mesoblast shares hit $4.45 in 2026?

How Robert Reffkin made Compass a powerhouse with the Anywhere acquisition. What's next in the battle with Zillow?